Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV)(Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV))

概要

基本信息

药物类型

变应原提取物

别名

Phleum pratense pollen allergy vaccine、Sublivac Fix Grasses、SUBLIVAC FIX Phleum pratense

靶点-

作用方式

调节剂

作用机制

免疫调节剂

治疗领域

免疫系统疾病感染眼部疾病+ [3]

在研适应症-

非在研适应症

艾滋病相关复合征过敏性鼻结膜炎变应性结膜炎+ [3]

原研机构

HAL Allergy Holding BV

在研机构-

非在研机构

HAL Allergy Holding BV

HAL Allergy BV

权益机构-

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV) 相关的临床试验

NCT02556801

/ Completed临床2期

A Single-center, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Investigate the Relative Efficacy and Safety of Immunotherapy With SUBLIVAC FIX Phleum Pratense in Grass Pollen-Allergic Subjects With IgE-Mediated Seasonal ARC

The purpose of this study is to assess safety, tolerability and demonstrate a dose response signal using Total Symptom Score (TSS), based on challenges with grass pollen in an Environmental Exposure Chamber (EEC), followed by estimation of the minimum effective dose of SUBLIVAC FIX Phleum (SP) after 10 months of treatment compared to placebo.
The study has 4 treatment groups: 3 different doses of SP and placebo will be tested.

开始日期2015-09-01

申办/合作机构

HAL Allergy Holding BV

EUCTR2010-021235-13-DE

/ Not yet recruitingN/A

A randomized, double-blind, placebo-controlled study to determine safety, tolerability and the optimal effective dose of SUBLIVAC FIX Phleum pratense in patients with allergic rhinitis/rhinoconjunctivitis caused by grass pollen - SUBLIVAC FIX Phleum pratense DT/DRF

开始日期2012-09-04

申办/合作机构-

NCT00422149

/ Completed临床3期

Twin SUBLIVAC® Grasses Clinical Efficacy Study

To show that treatment with SUBLIVAC® Grasses is clinically effective by means of reduction in allergic symptoms and/or use of allergic symptomatic medication in subjects suffering from IgE mediated allergic complaints triggered by grass pollen.

开始日期2006-09-01

申办/合作机构

HAL Allergy Holding BV

100 项与 Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV) 相关的临床结果

登录后查看更多信息

100 项与 Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV) 相关的转化医学

登录后查看更多信息

100 项与 Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV) 相关的专利（医药）

登录后查看更多信息

100 项与 Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
变应性结膜炎	临床3期	比利时	HAL Allergy Holding BV	2006-09-01
变应性结膜炎	临床3期	德国	HAL Allergy Holding BV	2006-09-01
变应性结膜炎	临床3期	荷兰	HAL Allergy Holding BV	2006-09-01
变应性结膜炎	临床3期	波兰	HAL Allergy Holding BV	2006-09-01
季节性过敏性鼻炎	临床3期	比利时	HAL Allergy Holding BV	2006-09-01
季节性过敏性鼻炎	临床3期	德国	HAL Allergy Holding BV	2006-09-01
季节性过敏性鼻炎	临床3期	荷兰	HAL Allergy Holding BV	2006-09-01
季节性过敏性鼻炎	临床3期	波兰	HAL Allergy Holding BV	2006-09-01
艾滋病相关复合征	临床2期	加拿大	HAL Allergy Holding BV	2015-09-01
口腔过敏综合征	临床2期	加拿大	HAL Allergy Holding BV	2015-09-01